KaloBios Pharmaceuticals (KBIO) Takes Upward Bounce; StemCells (STEM) Promising Clinical Data


KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) shares skyrocketed more than 700% to touch a new 52-week high in the extended session Wednesday after Turing Pharmaceuticals’ CEO Martin Shkreli disclosed in an SEC filing the purchase in the past couple days of 1,211,115 shares of the monoclonal antibody company

KaloBios, which recently reported that it will wind down its operations, confirmed that Martin Shkreli and associates acquired more than a 50% stake in the company, also saying that it has received a proposal from the group to continue its operations

KBIO stock closed the regular session at $2.07, down $0.10 (or -4.61%), with a total volume of 7,057,238 shares traded during the day

KaloBios Pharmaceuticals has 4.12M Shares Outstanding and KBIO stock 52-week range is between $0.44 and $16.00. At close on Wednesday, the company had a Market Capitalization of $8.54M.



Shares of StemCells Inc. (Nasdaq:STEM) soared over 45% in after-hours trading Wednesday as the company said that the six-month interim data from a study showed motor improvements in both strength and function in patients with cervical spinal cord injury, following cellular transplant

STEM stock finished the regular session at $0.455, up $0.005 (or +1.11%)

StemCells, a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, has 108.81M Shares Outstanding Market Capitalization (intraday) of $49.51M and STEM stock one-year range is $0.31 – $1.39 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/